Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. has announced the granting of a crucial patent for its FAK inhibitor, narmafotinib, in Europe and Japan, extending its market protection until at least 2040. This patent covers the chemical form of narmafotinib that is currently undergoing clinical trials, including the Phase 2a ACCENT trial for advanced pancreatic cancer. The company expects this development to significantly enhance the commercial longevity and potential of narmafotinib in the global market.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
